Janna Flint Wilson
Pediatric Endocrinology · Lafayette, LANPI 1447325360
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 286 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 32 manufacturers reported payments, led by Dexcom, Inc. at 29.8% of the total. 2025 is the largest year on record at $1,457, 2.5 times the $586 reported in 2019.
Across 286 payments — averaging $17.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dexcom, Inc.$1K
- Insulet Corporation$502
- Tolmar, Inc.$352
- Neurocrine Biosciences, Inc.$272
- Ascendis Pharma Endocrinology Inc$258
- Medtronic$233
- plus $2K from 26 others
What the payments were for
- Food & beverage$4,97299%
- Education$271%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dexcom, Inc. | 117 | $1,492 |
| Insulet Corporation | 25 | $502 |
| Tolmar, Inc. | 16 | $352 |
| Neurocrine Biosciences, Inc. | 13 | $272 |
| Ascendis Pharma Endocrinology Inc | 11 | $258 |
| Medtronic(2 entities) | 13 | $233 |
| Kyowa Kirin, Inc. | 7 | $188 |
| Novo Nordisk | 8 | $168 |
| AbbVie | 10 | $150 |
| Sanofi-aventis U.S. LLC | 6 | $147 |
| Tandem Diabetes Care, Inc. | 5 | $134 |
| AstraZeneca | 2 | $84 |
| Endo Pharmaceuticals Inc. | 4 | $82 |
| Xeris Pharmaceuticals, Inc. | 4 | $78 |
| Lilly USA, LLC | 5 | $76 |
| Tolmar Pharmaceuticals, Inc. | 3 | $68 |
| Amneal Pharmaceuticals LLC | 3 | $68 |
| Soleno Therapeutics, Inc. | 3 | $66 |
| BETA Bionics, Inc. | 3 | $61 |
| Amphastar Pharmaceuticals, Inc. | 3 | $58 |
| Azurity Pharmaceuticals, Inc. | 3 | $55 |
| Ultragenyx Pharmaceutical Inc. | 3 | $54 |
| Pfizer | 3 | $51 |
| Ferring Pharmaceuticals Inc. | 3 | $43 |
| Companion Medical, Inc. | 2 | $41 |
| Ipsen Biopharmaceuticals, Inc | 2 | $40 |
| Arbor Pharmaceuticals, Inc. | 2 | $38 |
| Endo USA, Inc. | 2 | $37 |
| BD | 2 | $31 |
| Biomarin Pharmaceutical Inc. | 1 | $30 |
| Abbott | 1 | $22 |
| Sequel Med Tech, LLC | 1 | $19 |
How this compares
Too few pediatric endocrinology providers in Louisianato place this figure against a meaningful peer group, so we don't.
Other pediatric endocrinology in Lafayette
- Stuart ChalewNew Orleans$7K
- Ricardo GomezNew Orleans$6K
- Cielo AlleynNew Orleans$3K
- Dania Felipe-RamirezNew Orleans$3K
- Sasi PenukondaShreveport$2K
- Arlette Soros DupreNew Orleans$2K
- Chantal LutfallahBaton Rouge$2K
- In-Sian PouwLacombe$2K
- James GardnerBaton Rouge$2K
- Snigdha LikkiShreveport$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.